Stay updated on AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.

Latest updates to the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page
- Check4 days agoNo Change Detected
- Check12 days agoNo Change Detected
- Check19 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check26 days agoNo Change Detected
- Check34 days agoChange DetectedThe page has been updated to focus on a new study involving untreated metastatic pancreatic ductal adenocarcinoma, highlighting the drugs Cisplatin and Gemcitabine, while removing extensive details about a previous study involving multiple drugs and criteria.SummaryDifference30%
- Check41 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check84 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check99 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check106 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AK104+Lenvatinib in Advanced Hepatocellular Carcinoma Clinical Trial page.